TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07723469: Phase 3 Trial of SRG-514 Administered Intraoperatively to Patients Undergoing Breast-Conserving Surgery

Sponsor: SURGE Therapeutics · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 400 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$20,993,280

Rescue Site Savings

+$13,842,444

Unlock Full NCT07723469 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07723469 Rescue Dossier →